EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer

A Borque-Fernando, D A Pérez-Fentes, M Rodrigo-Aliaga, J Puente-Vázquez, A Gómez-Iturriaga, M Unda, M A Calleja-Hernández, J M Cózar-Olmo, J L Álvarez-Ossorio

Actas Urológicas Españolas (English Edition) · 2024

DOI: 10.1016/j.acuroe.2024.10.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Urológicas Españolas (English Edition), 2024. Verfasst von A Borque-Fernando und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Urología, Hospital Universitario Miguel Servet, IIS-Aragón, Zaragoza, Spain. Electronic address: dr.borque@gmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists. Die Arbeit nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleDocetaxelAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisTaxoidsAndrogen Receptor Antagonists

Stichwörter der Autor:innen

Androgen antagonistsAntagonistas de andrógenosConsensoConsensusCáncer de la próstataDisease managementDocetaxelExpert testimonyManejo de la enfermedadProstatic neoplasmsTestimonio de experto

Substanzen

Androgen AntagonistsDocetaxelTaxoidsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Servicio de Urología, Hospital Universitario Miguel Servet, IIS-Aragón, Zaragoza, Spain. Electronic address: dr.borque@gmail.com.
  • Servicio de Urología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
  • Servicio de Urología, Hospital General Universitario de Castellón, Castellón, Spain.
  • Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain.
  • Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Biocruces Bizkaia Health Research Insitute, Barakaldo, Bizkaia, Spain.
  • Laboratorio Mixto de Investigación Traslacional en Cáncer de Próstata Cic bioGUNE-Basurto, IIS Biobizkaia, Basurto, Bizkaia, Spain.

Zitieren

APA

Borque-Fernando, A., Pérez-Fentes, D. A., Rodrigo-Aliaga, M., Puente-Vázquez, J., Gómez-Iturriaga, A., Unda, M., Calleja-Hernández, M. A., Cózar-Olmo, J. M., & Álvarez-Ossorio, J. L. (2024). Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer. Actas Urológicas Españolas (English Edition). https://doi.org/10.1016/j.acuroe.2024.10.005

Vancouver

Borque-Fernando A, Pérez-Fentes DA, Rodrigo-Aliaga M, Puente-Vázquez J, Gómez-Iturriaga A, Unda M, et al. Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer. Actas Urológicas Españolas (English Edition). 2024. doi:10.1016/j.acuroe.2024.10.005

BibTeX
@article{BorqueFernando2024,
  author = {Borque-Fernando, A and Pérez-Fentes, D A and Rodrigo-Aliaga, M and Puente-Vázquez, J and Gómez-Iturriaga, A and Unda, M and Calleja-Hernández, M A and Cózar-Olmo, J M and Álvarez-Ossorio, J L},
  title = {Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer},
  journal = {Actas Urológicas Españolas (English Edition)},
  year = {2024},
  doi = {10.1016/j.acuroe.2024.10.005}
}
Kostenlos starten →